A Phase 3 interventional study of Xanomeline and Trospium Chloride Capsules and Placebo in Schizophrenia, sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company. Completed at 28 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-12-17.
Sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing xanomeline in Schizophrenia — 9 open to participants now, 9 under way, 4 of them phase 3. xanomeline · Schizophrenia.
Among the 20 studies testing xanomeline in Schizophrenia, this one is the 9th largest by enrollment, is the only one that started in 2023, is one of 14 in phase 3, and was the 9th registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →9 of the 20 studies testing xanomeline in Schizophrenia are open now, in 12 countries. Recruiting first, the newest first:
Karuna Therapeutics, Inc., a Bristol Myers Squibb company · Sites in United States, Argentina, Bulgaria and 4 more countries
Ages 18–65
New York State Psychiatric Institute · Sites in United States
Ages 18–50
Karuna Therapeutics, Inc., a Bristol Myers Squibb company · Sites in United States, Australia, Canada and 8 more countries
Ages 5–17
Bristol-Myers Squibb · Sites in United States, Colombia, Japan and 1 more country
Ages 13–17
Bristol-Myers Squibb · Sites in United States
Ages 18–65
By country, each count listing its studies:
xanomeline: first FDA approval 2024 (COBENFY). What it is approved for, and how studies give it, is on its page →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 14 · Phase 4 3
First in 2018; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 202 is above the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 178 across the 20 interventional studies. Of the 10 that completed or were terminated, 9 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 20 have an industry lead sponsor. The 7 most frequent:
This study is registered under Karuna Therapeutics, Inc., a Bristol Myers Squibb company, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Karuna Therapeutics, Inc., a Bristol Myers Squibb company is the lead sponsor of 17 studies on the registry; 8 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 4 (44%) have results posted.
21 studies in Schizophrenia by Bristol-Myers Squibb: 8 open now, 9 under way, 4 of them phase 3. Of 12 finished, 9 (75%) have results posted.
Among the 21 studies in Schizophrenia by Bristol-Myers Squibb, this one is the 9th largest by enrollment of the 17 interventional ones that give a count, is the only one that started in 2023, is one of 13 in phase 3, and was the 10th registered.
Bristol-Myers Squibb’s Schizophrenia studies by the year they started, since 2016.
2 of the studies testing xanomeline in Schizophrenia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07423546New York State Psychiatric InstituteA PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia | 2027-04-30 |
| NCT07061288Bristol-Myers SquibbA Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT | 2027-06-21 |
Add all 2 to your calendar (.ics) → With an account.
Among the 20 studies testing xanomeline in Schizophrenia, from their registry updates:
Among Bristol-Myers Squibb’s 21 in Schizophrenia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A Phase 3, Multicenter, Two-part Study with a 5-week Double-blind Part (Randomized, Parallel-group, Placebo-controlled) followed by a 12-week Open-label Extension Part, to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects with DSM-5 Schizophrenia
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject is experiencing an acute exacerbation or relapse of psychotic symptoms, with onset less than 2 months before screening.
PANSS total score between 80 and 120,inclusive, with a scores of ≥4 (moderate or greater) for ≥2 of the following Positive Scale (P) items:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Xanomeline and Trospium Chloride Capsules
Drug: Placebo
Drug pages: Xanomeline · Trospium chloride
Oral xanomeline 50 mg/trospium 20 mg BID on days 1-2 followed by xanomeline 100 mg/trospium 20 mg BID on days 3-7. The dose is increased to xanomeline 125 mg/trospium 30 mg BID on days 8-35 unless the subject is experiencing adverse events from the xanomeline 100 mg/ trospium 20 mg dose. Subjects who were increased to xanomeline 125 mg/trospium 30 mg will have the option to return to xanomeline 100 mg/ trospium 20 mg depending on clinical response and tolerability.
Also known as: KarXT
Placebo Capsules
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Scores at Week 5 of the Double-Blind Period
PANSS Total Score is a clinical tool used to measure the severity of symptoms in individuals with schizophrenia. It includes 30 items divided into three subscales: Positive Symptoms (e.g., hallucinations, delusions) Negative Symptoms (e.g., social withdrawal, lack of motivation) General Psychopathology (e.g., anxiety, depression) Each item is rated from 1 (absent) to 7 (extreme), resulting in a total score range from 30 to 210. Higher PANSS Total Scores indicate more severe symptoms and worse clinical outcomes. Baseline is defined as last non-missing assessment prior to the first dose of study drug.
Time frame: At Baseline and at Week 5 of the Double-Blind Period
Change From Baseline in Positive Symptom Score of the Positive and Negative Syndrome Scale (PANSS) at Week 5 of the Double-Blind Period
The PANSS Positive Symptom Score assesses the severity of positive symptoms in schizophrenia, such as hallucinations and delusions. It includes 7 items: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. Each item is rated from 1 (absent) to 7 (extreme), for a total score range of 7 to 49. Higher scores indicate more severe symptoms and worse clinical outcomes. Baseline is defined as last non-missing assessment prior to the first dose of study drug.
Time frame: At Baseline and at Week 5 of the Double-Blind Period
Change From Baseline in Negative Symptom Score of the Positive and Negative Syndrome Scale (PANSS) at Week 5 of the Double-Blind Period
The Positive and Negative Syndrome Scale (PANSS) Negative Symptom Score assesses the severity of negative symptoms in schizophrenia, such as emotional withdrawal and reduced motivation. It includes 7 items: blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity, and stereotyped thinking. Each item is rated from 1 (absent) to 7 (extreme), for a total score range of 7 to 49. Higher scores indicate more severe symptoms and worse outcomes. Baseline is defined as last non-missing assessment prior to the first dose of study drug.
Time frame: At Baseline and at Week 5 of the Double-Blind Period
Change From Baseline in Negative Marder Factor Score of the Positive and Negative Syndrome Scale (PANSS) at Week 5 of the Double-Blind Period
The Negative Marder Factor Score is subset of PANSS items used to evaluate negative symptoms based on a five-factor model. It includes 7 items: blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of spontaneity, motor retardation, and active social avoidance. Each item is rated from 1 to 7. Higher scores reflect greater severity of negative symptoms and poorer clinical outcomes. PANSS total score is the sum of all 30 items with a minimum score of 30 and a maximum score of 210. Higher scores indicate more severe symptoms. The PANSS Total Score is then the sum of the positive, negative, and general psychopathology symptom scores. Baseline is defined as last non-missing assessment prior to the first dose of study drug.
Time frame: At Baseline and at Week 5 of the Double-Blind Period
Change From Baseline in Clinical Global Impressions - Severity (CGI-S) Score at Week 5 of the Double-Blind Period
The CGI-S Score is a clinician-rated scale used to assess the severity of a patient's mental illness at a given time. It ranges from 1 (Normal, not at all ill) to 7 (Among the most extremely ill patients). The score reflects the clinician's overall impression based on observed symptoms, behavior, and functioning. Higher scores indicate greater illness severity and worse clinical status. Baseline is defined as last non-missing assessment prior to the first dose of study drug.
Time frame: At Baseline and at Week 5 of the Double-Blind Period
Percentage of PANSS Responders (≥30% Change in PANSS Total Score From Baseline) at Week 5 of the Double-Blind Period
PANSS Total Score is a clinical tool used to measure the severity of symptoms in individuals with schizophrenia. It includes 30 items divided into three subscales: Positive Symptoms (e.g., hallucinations, delusions) Negative Symptoms (e.g., social withdrawal, lack of motivation) General Psychopathology (e.g., anxiety, depression) Each item is rated from 1 (absent) to 7 (extreme), resulting in a total score range from 30 to 210. Higher PANSS Total Scores indicate more severe symptoms and worse clinical outcomes. Baseline is defined as last non-missing assessment prior to the first dose of study drug.
Time frame: At Baseline and at Week 5 of the Double-Blind Period
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Scores at Week 12 of the Open-Label Period
PANSS Total Score is a clinical tool used to measure the severity of symptoms in individuals with schizophrenia. It includes 30 items divided into three subscales: Positive Symptoms (e.g., hallucinations, delusions) Negative Symptoms (e.g., social withdrawal, lack of motivation) General Psychopathology (e.g., anxiety, depression) Each item is rated from 1 (absent) to 7 (extreme), resulting in a total score range from 30 to 210. Higher PANSS Total Scores indicate more severe symptoms and worse clinical outcomes. Study baseline is defined as last non-missing assessment prior to the first dose of study drug. Open-label baseline is defined as last non-missing assessment prior to the first dose of study drug in the open-label part.
Time frame: At Baseline and at Week 12 of the Open-Label Period
Change From Baseline in Positive Symptom Score of the Positive and Negative Syndrome Scale (PANSS) at Week 12 of the Open-Label Period
The PANSS Positive Symptom Score assesses the severity of positive symptoms in schizophrenia, such as hallucinations and delusions. It includes 7 items: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. Each item is rated from 1 (absent) to 7 (extreme), for a total score range of 7 to 49. Higher scores indicate more severe symptoms and worse clinical outcomes. Study baseline is defined as last non-missing assessment prior to the first dose of study drug. Open-label baseline is defined as last non-missing assessment prior to the first dose of study drug in the open-label part.
Time frame: At Baseline and at Week 12 of the Open-Label Period
Change From Baseline in Negative Symptom Score of the Positive and Negative Syndrome Scale (PANSS) at Week 12 of the Open-Label Period
The Positive and Negative Syndrome Scale (PANSS) Negative Symptom Score assesses the severity of negative symptoms in schizophrenia, such as emotional withdrawal and reduced motivation. It includes 7 items: blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity, and stereotyped thinking. Each item is rated from 1 (absent) to 7 (extreme), for a total score range of 7 to 49. Higher scores indicate more severe symptoms and worse outcomes. Study baseline is defined as last non-missing assessment prior to the first dose of study drug. Open-label baseline is defined as last non-missing assessment prior to the first dose of study drug in the open-label part.
Time frame: At Baseline and at Week 12 of the Open-Label Period
Change From Baseline in Negative Marder Factor Score of the Positive and Negative Syndrome Scale (PANSS) at Week 12 of the Open-Label Period
The Negative Marder Factor Score is subset of PANSS items used to evaluate negative symptoms based on a five-factor model. It includes 7 items: blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of spontaneity, motor retardation, and active social avoidance. Each item is rated from 1 to 7. Higher scores reflect greater severity of negative symptoms and poorer clinical outcomes. Study baseline is defined as last non-missing assessment prior to the first dose of study drug. Open-label baseline is defined as last non-missing assessment prior to the first dose of study drug in the open-label part.
Time frame: At Baseline and at Week 12 of the Open-Label Period
Change From Baseline in Clinical Global Impressions - Severity (CGI-S) Score at Week 12 of the Open-Label Period
The CGI-S Score is a clinician-rated scale used to assess the severity of a patient's mental illness at a given time. It ranges from 1 (Normal, not at all ill) to 7 (Among the most extremely ill patients). The score reflects the clinician's overall impression based on observed symptoms, behavior, and functioning. Higher scores indicate greater illness severity and worse clinical status. Study baseline is defined as last non-missing assessment prior to the first dose of study drug. Open-label baseline is defined as last non-missing assessment prior to the first dose of study drug in the open-label part.
Time frame: At Baseline and at Week 12 of the Open-Label Period
Percentage of PANSS Responders (≥30% Change in PANSS Total Score From Baseline) at Week 12 of the Open-Label Period
PANSS Total Score is a clinical tool used to measure the severity of symptoms in individuals with schizophrenia. It includes 30 items divided into three subscales: Positive Symptoms (e.g., hallucinations, delusions) Negative Symptoms (e.g., social withdrawal, lack of motivation) General Psychopathology (e.g., anxiety, depression) Each item is rated from 1 (absent) to 7 (extreme), resulting in a total score range from 30 to 210. Higher PANSS Total Scores indicate more severe symptoms and worse clinical outcomes. Study baseline is defined as last non-missing assessment prior to the first dose of study drug. Open-label baseline is defined as last non-missing assessment prior to the first dose of study drug in the open-label part.
Time frame: At Baseline and at Week 12 of the Open-Label Period
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs Leading to Study Drug Withdrawal
Adverse Event (AE): An AE is any unfavorable and unintended sign, symptom, or disease that occurs in a participant during a clinical trial, regardless of whether it is related to the study treatment. This includes new conditions or worsening of pre-existing ones. Serious Adverse Event (SAE): An SAE is an AE that results in death, is life-threatening, requires hospitalization or prolongs existing hospitalization, causes persistent or significant disability/incapacity, or leads to a congenital anomaly/birth defect. Other events may be considered serious if they require medical intervention to prevent one of these outcomes.
Time frame: From first dose until study completion (up to approximately 18 weeks)
Number of Participants With Orthostatic Vital Sign Events
Orthostatic vital signs included blood pressure and heart rate. A participant having sustained orthostatic event is defined as the participant experienced at least one orthostatic event for at least 3 consecutive visits.
Time frame: From first dose until study completion (up to approximately 18 weeks)
Number of Participants With Elevated Liver Function Test Results
ULN = upper limit of normal range.; DB = Double-blind period; OL = Open-label period. Hy's law is defined as an elevated alanine aminotransferase level (\>3xULN) or an elevated aspartate aminotransferase (\>3xULN) in combination with alkaline phosphatase \<2xULN and elevated total bilirubin (\>2 x ULN). Study baseline is defined as last non-missing assessment prior to the first dose of study drug. Open-label baseline is defined as last non-missing assessment prior to the first dose of study drug in the open-label part.
Time frame: At study baseline, Day 21 DB, Day 35 DB, open-label baseline, Day 14 OL, Day 84 OL, and end of study visit (up to approximately 18 weeks)
Number of Participants With Elevated Metabolic Syndrome Parameters
ULN = Upper limit of normal; DB = Double-blind period; OL = Open-label period. Study baseline is defined as last non-missing assessment prior to the first dose of study drug. Open-label baseline is defined as last non-missing assessment prior to the first dose of study drug in the open-label part.
Time frame: At study baseline, Day 21 DB, Day 35 DB, open-label baseline, Day 14 OL, Day 84 OL, and end of study visit (up to approximately 18 weeks)
Number of Participants With Abnormal Electrocardiogram (ECG) Results
Anytime post-baseline includes all assessments from the first dose of study drug until end of study visit in double-blind/open-label part, including unscheduled assessments. Study baseline is defined as last non-missing assessment prior to the first dose of study drug. Open-label baseline is defined as last non-missing assessment prior to the first dose of study drug in the open-label part.
Time frame: At study baseline and up to study completion (up to approximately 18 weeks)
Number of Participants With Suicidal Ideation as Defined by a Columbia-Suicide Severity Rating Scale (C-SSRS) Ideation Score of 1 or Greater
The C-SSRS is a clinician- or self-administered questionnaire assessing suicidal ideation and behavior. It rates ideation severity from 1 (wish to be dead) to 5 (active suicidal ideation with specific plan and intent). It also records the presence or absence of suicidal behaviors, including actual, interrupted, or aborted attempts, and preparatory acts. The highest level of ideation or most severe behavior reported is used to determine suicide risk; higher ideation scores or any suicidal behavior indicate greater risk. Baseline is the last non-missing assessment before first study drug dose.
Time frame: From first dose to study completion (up to approximately 18 weeks)
Number of Participants With Clinically Meaningful Changes in Simpson-Angus Scale (SAS), Barnes Akathisia Rating Scale (BARS), and Abnormal Involuntary Movement Scale (AIMS) Results
Treatment-emergent parkinsonism is defined as Simpson-Angus Scale total score \>3 with a baseline score ≤3. Treatment-emergent akathisia is defined as Barnes Akathisia Rating Scale global clinical assessment score \>2 with a baseline score ≤2. Treatment-emergent dyskinesia is defined as any Abnormal Involuntary Movement Scale (AIMS) item 1-7 score ≥3 with a baseline score \<3 for the item, or score ≥2 on two or more of AIMS items 1-7 with baseline \<2 for the items. Study baseline is defined as last non-missing assessment prior to the first dose of study drug. Open-label baseline is defined as last non-missing assessment prior to the first dose of study drug in the open-label part.
Time frame: At study baseline, open-label baseline, and up to study completion (up to approximately 18 weeks)
Change From Baseline in Body Weight
Study baseline is defined as last non-missing assessment prior to the first dose of study drug. Open-label baseline is defined as last non-missing assessment prior to the first dose of study drug in the open-label part.
Time frame: At study baseline, Day 35 DB, open-label baseline, Day 84 OL, and end of study visit (up to approximately 18 weeks)
Change From Baseline in Body Mass Index (BMI)
Study baseline is defined as last non-missing assessment prior to the first dose of study drug. Open-label baseline is defined as last non-missing assessment prior to the first dose of study drug in the open-label part.
Time frame: At study baseline, Day 35 DB, open-label baseline, Day 84 OL, and end of study visit (up to approximately 18 weeks)
Change From Baseline in Waist Circumference
Study baseline is defined as last non-missing assessment prior to the first dose of study drug. Open-label baseline is defined as last non-missing assessment prior to the first dose of study drug in the open-label part.
Time frame: At study baseline, Day 35 DB, open-label baseline, Day 84 OL, and end of study visit (up to approximately 18 months)
Area Under the Concentration-Time Curve (AUC0-12) of Xanomeline and Trospium - Double-Blind Period
AUC₀-12 (Area Under the Concentration-Time Curve from time zero to 12 hours) is the total amount of drug in the blood measured from the time the drug is given (time zero) up to 12 hours after dosing.
Time frame: On Day 28 of the Double-Blind Period
Maximum Observed Plasma Concentration (Cmax) of Xanomeline and Trospium - Double-Blind Period
Cmax is the highest concentration of a drug measured in the blood after it is given.
Time frame: On Day 28 of the Double-Blind Period
Time to Cmax (Tmax) of Xanomeline and Trospium - Double-Blind Period
Tmax is the amount of time it takes to reach that highest concentration (Cmax) after the drug is given.
Time frame: On Day 28 of the Double-Blind Period
| Milestone | Double-Blind Part: KarXT | Double-Blind Part: Placebo | Open-Label Part: KarXT/KarXT | Open-Label Part: Placebo/KarXT |
|---|---|---|---|---|
| Started | 103 | 99 | 0 | 0 |
| Completed | 102 | 98 | 0 | 0 |
| Not completed | 1 | 1 | 0 | 0 |
| Withdrew: Screen failure | 1 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 0 |
| Milestone | Double-Blind Part: KarXT | Double-Blind Part: Placebo | Open-Label Part: KarXT/KarXT | Open-Label Part: Placebo/KarXT |
|---|---|---|---|---|
| Started | 102 | 98 | 0 | 0 |
| Completed | 79 | 78 | 0 | 0 |
| Not completed | 23 | 20 | 0 | 0 |
| Withdrew: Adverse event | 8 | 9 | 0 | 0 |
| Withdrew: Protocol violation | 2 | 1 | 0 | 0 |
| Withdrew: Participant withdrew consent | 11 | 7 | 0 | 0 |
| Withdrew: Other reasons | 2 | 3 | 0 | 0 |
| Milestone | Double-Blind Part: KarXT | Double-Blind Part: Placebo | Open-Label Part: KarXT/KarXT | Open-Label Part: Placebo/KarXT |
|---|---|---|---|---|
| Started | 0 | 0 | 38 | 28 |
| Completed | 0 | 0 | 18 | 11 |
| Not completed | 0 | 0 | 20 | 17 |
| Withdrew: Adverse event | 0 | 0 | 2 | 4 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 1 |
| Withdrew: Participant withdrew consent | 0 | 0 | 8 | 6 |
| Withdrew: Death | 0 | 0 | 0 | 1 |
| Withdrew: Other reasons | 0 | 0 | 9 | 5 |
PANSS Total Score is a clinical tool used to measure the severity of symptoms in individuals with schizophrenia. It includes 30 items divided into three subscales: Positive Symptoms (e.g., hallucinations, delusions) Negative Symptoms (e.g., social withdrawal, lack of motivation) General Psychopathology (e.g., anxiety, depression) Each item is rated from 1 (absent) to 7 (extreme), resulting in a total score range from 30 to 210. Higher PANSS Total Scores indicate more severe symptoms and worse clinical outcomes. Baseline is defined as last non-missing assessment prior to the first dose of study drug.
| Score on a Scale | Double-Blind Part: KarXT | Double-Blind Part: Placebo |
|---|---|---|
| Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Scores at Week 5 of the Double-Blind Period | -16.9 ± 2.122 | -7.7 ± 2.074 |
The PANSS Positive Symptom Score assesses the severity of positive symptoms in schizophrenia, such as hallucinations and delusions. It includes 7 items: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. Each item is rated from 1 (absent) to 7 (extreme), for a total score range of 7 to 49. Higher scores indicate more severe symptoms and worse clinical outcomes. Baseline is defined as last non-missing assessment prior to the first dose of study drug.
| Score on a Scale | Double-Blind Part: KarXT | Double-Blind Part: Placebo |
|---|---|---|
| Change From Baseline in Positive Symptom Score of the Positive and Negative Syndrome Scale (PANSS) at Week 5 of the Double-Blind Period | -6.5 ± 0.713 | -4.6 ± 0.700 |
The Positive and Negative Syndrome Scale (PANSS) Negative Symptom Score assesses the severity of negative symptoms in schizophrenia, such as emotional withdrawal and reduced motivation. It includes 7 items: blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity, and stereotyped thinking. Each item is rated from 1 (absent) to 7 (extreme), for a total score range of 7 to 49. Higher scores indicate more severe symptoms and worse outcomes. Baseline is defined as last non-missing assessment prior to the first dose of study drug.
| Score on a Scale | Double-Blind Part: KarXT | Double-Blind Part: Placebo |
|---|---|---|
| Change From Baseline in Negative Symptom Score of the Positive and Negative Syndrome Scale (PANSS) at Week 5 of the Double-Blind Period | -3.2 ± 0.664 | -0.7 ± 0.648 |
The Negative Marder Factor Score is subset of PANSS items used to evaluate negative symptoms based on a five-factor model. It includes 7 items: blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of spontaneity, motor retardation, and active social avoidance. Each item is rated from 1 to 7. Higher scores reflect greater severity of negative symptoms and poorer clinical outcomes. PANSS total score is the sum of all 30 items with a minimum score of 30 and a maximum score of 210. Higher scores indicate more severe symptoms. The PANSS Total Score is then the sum of the positive, negative, and general psychopathology symptom scores. Baseline is defined as last non-missing assessment prior to the first dose of study drug.
| Score on a Scale | Double-Blind Part: KarXT | Double-Blind Part: Placebo |
|---|---|---|
| Change From Baseline in Negative Marder Factor Score of the Positive and Negative Syndrome Scale (PANSS) at Week 5 of the Double-Blind Period | -3.1 ± 0.677 | -0.5 ± 0.660 |
The CGI-S Score is a clinician-rated scale used to assess the severity of a patient's mental illness at a given time. It ranges from 1 (Normal, not at all ill) to 7 (Among the most extremely ill patients). The score reflects the clinician's overall impression based on observed symptoms, behavior, and functioning. Higher scores indicate greater illness severity and worse clinical status. Baseline is defined as last non-missing assessment prior to the first dose of study drug.
| Score on a Scale | Double-Blind Part: KarXT | Double-Blind Part: Placebo |
|---|---|---|
| Change From Baseline in Clinical Global Impressions - Severity (CGI-S) Score at Week 5 of the Double-Blind Period | -0.9 ± 0.119 | -0.5 ± 0.117 |
PANSS Total Score is a clinical tool used to measure the severity of symptoms in individuals with schizophrenia. It includes 30 items divided into three subscales: Positive Symptoms (e.g., hallucinations, delusions) Negative Symptoms (e.g., social withdrawal, lack of motivation) General Psychopathology (e.g., anxiety, depression) Each item is rated from 1 (absent) to 7 (extreme), resulting in a total score range from 30 to 210. Higher PANSS Total Scores indicate more severe symptoms and worse clinical outcomes. Baseline is defined as last non-missing assessment prior to the first dose of study drug.
| Percentage of participants | Double-Blind Part: KarXT | Double-Blind Part: Placebo |
|---|---|---|
| Percentage of PANSS Responders (≥30% Change in PANSS Total Score From Baseline) at Week 5 of the Double-Blind Period | 42.1 | 26.3 |
PANSS Total Score is a clinical tool used to measure the severity of symptoms in individuals with schizophrenia. It includes 30 items divided into three subscales: Positive Symptoms (e.g., hallucinations, delusions) Negative Symptoms (e.g., social withdrawal, lack of motivation) General Psychopathology (e.g., anxiety, depression) Each item is rated from 1 (absent) to 7 (extreme), resulting in a total score range from 30 to 210. Higher PANSS Total Scores indicate more severe symptoms and worse clinical outcomes. Study baseline is defined as last non-missing assessment prior to the first dose of study drug. Open-label baseline is defined as last non-missing assessment prior to the first dose of study drug in the open-label part.
| Score on a Scale | Open-Label Part: KarXT/KarXT | Open-Label Part: Placebo/KarXT |
|---|---|---|
| Study baseline to Open-label period- Week 12 | -22.0 ± 21.67 | -21.2 ± 19.76 |
| Open-label period- baseline to Open-label period- Week 12 | -2.7 ± 17.27 | -6.1 ± 12.49 |
The PANSS Positive Symptom Score assesses the severity of positive symptoms in schizophrenia, such as hallucinations and delusions. It includes 7 items: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. Each item is rated from 1 (absent) to 7 (extreme), for a total score range of 7 to 49. Higher scores indicate more severe symptoms and worse clinical outcomes. Study baseline is defined as last non-missing assessment prior to the first dose of study drug. Open-label baseline is defined as last non-missing assessment prior to the first dose of study drug in the open-label part.
| Score on a Scale | Open-Label Part: KarXT/KarXT | Open-Label Part: Placebo/KarXT |
|---|---|---|
| Study baseline to Open-label period - Week 12 | -6.9 ± 6.09 | -8.2 ± 6.65 |
| Open-label period- baseline to Open-label period- Week 12 | -0.2 ± 5.31 | -0.8 ± 4.64 |
The Positive and Negative Syndrome Scale (PANSS) Negative Symptom Score assesses the severity of negative symptoms in schizophrenia, such as emotional withdrawal and reduced motivation. It includes 7 items: blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity, and stereotyped thinking. Each item is rated from 1 (absent) to 7 (extreme), for a total score range of 7 to 49. Higher scores indicate more severe symptoms and worse outcomes. Study baseline is defined as last non-missing assessment prior to the first dose of study drug. Open-label baseline is defined as last non-missing assessment prior to the first dose of study drug in the open-label part.
| Score on a Scale | Open-Label Part: KarXT/KarXT | Open-Label Part: Placebo/KarXT |
|---|---|---|
| Study baseline to Open-label period- Week 12 | -4.3 ± 7.75 | -3.0 ± 7.40 |
| Open-label period- baseline to Open-label period- Week 12 | -0.4 ± 5.64 | -1.4 ± 4.88 |
The Negative Marder Factor Score is subset of PANSS items used to evaluate negative symptoms based on a five-factor model. It includes 7 items: blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of spontaneity, motor retardation, and active social avoidance. Each item is rated from 1 to 7. Higher scores reflect greater severity of negative symptoms and poorer clinical outcomes. Study baseline is defined as last non-missing assessment prior to the first dose of study drug. Open-label baseline is defined as last non-missing assessment prior to the first dose of study drug in the open-label part.
| Score on a Scale | Open-Label Part: KarXT/KarXT | Open-Label Part: Placebo/KarXT |
|---|---|---|
| Study baseline to Open-label period- Week 12 | -3.9 ± 7.40 | -3.0 ± 7.25 |
| Open-label period- baseline to Open-label period- Week 12 | -0.2 ± 5.43 | -0.8 ± 4.49 |
The CGI-S Score is a clinician-rated scale used to assess the severity of a patient's mental illness at a given time. It ranges from 1 (Normal, not at all ill) to 7 (Among the most extremely ill patients). The score reflects the clinician's overall impression based on observed symptoms, behavior, and functioning. Higher scores indicate greater illness severity and worse clinical status. Study baseline is defined as last non-missing assessment prior to the first dose of study drug. Open-label baseline is defined as last non-missing assessment prior to the first dose of study drug in the open-label part.
| Score on a Scale | Open-Label Part: KarXT/KarXT | Open-Label Part: Placebo/KarXT |
|---|---|---|
| Study baseline to Open-label period- Week 12 | -1.1 ± 1.06 | -1.2 ± 0.98 |
| Open-label period- baseline to Open-label period- Week 12 | -0.1 ± 0.80 | -0.5 ± 0.82 |
PANSS Total Score is a clinical tool used to measure the severity of symptoms in individuals with schizophrenia. It includes 30 items divided into three subscales: Positive Symptoms (e.g., hallucinations, delusions) Negative Symptoms (e.g., social withdrawal, lack of motivation) General Psychopathology (e.g., anxiety, depression) Each item is rated from 1 (absent) to 7 (extreme), resulting in a total score range from 30 to 210. Higher PANSS Total Scores indicate more severe symptoms and worse clinical outcomes. Study baseline is defined as last non-missing assessment prior to the first dose of study drug. Open-label baseline is defined as last non-missing assessment prior to the first dose of study drug in the open-label part.
| Percentage of participants | Open-Label Part: KarXT/KarXT | Open-Label Part: Placebo/KarXT |
|---|---|---|
| Study baseline to Open-label period- Week 12 | 66.7 | 45.5 |
| Open-label period- baseline to Open-label period- Week 12 | 16.7 | 27.3 |
Adverse Event (AE): An AE is any unfavorable and unintended sign, symptom, or disease that occurs in a participant during a clinical trial, regardless of whether it is related to the study treatment. This includes new conditions or worsening of pre-existing ones. Serious Adverse Event (SAE): An SAE is an AE that results in death, is life-threatening, requires hospitalization or prolongs existing hospitalization, causes persistent or significant disability/incapacity, or leads to a congenital anomaly/birth defect. Other events may be considered serious if they require medical intervention to prevent one of these outcomes.
| Participants | Double-Blind Part: KarXT | Double-Blind Part: Placebo | Open-Label Part: KarXT/KarXT | Open-Label Part: Placebo/KarXT |
|---|---|---|---|---|
| Adverse events | 97 | 90 | 33 | 28 |
| Serious adverse events | 0 | 3 | 0 | 3 |
| Adverse events leading to drug withdrawal | 8 | 9 | 2 | 4 |
Orthostatic vital signs included blood pressure and heart rate. A participant having sustained orthostatic event is defined as the participant experienced at least one orthostatic event for at least 3 consecutive visits.
| Participants | Double-Blind Part: KarXT | Double-Blind Part: Placebo | Open-Label Part: KarXT/KarXT | Open-Label Part: Placebo/KarXT |
|---|---|---|---|---|
| Orthostatic event at any visit | 36 | 31 | 8 | 5 |
| A Decrease in Systolic Blood Pressure of ≥ 20 mmHg | 21 | 10 | 2 | 2 |
| A Decrease in Diastolic Blood Pressure of ≥ 10 mmHg | 16 | 16 | 4 | 5 |
| An Increase in Heart Rate of ≥ 30 bpm | 9 | 12 | 2 | 0 |
| Sustained orthostatic events | 3 | 2 | 0 | 0 |
ULN = upper limit of normal range.; DB = Double-blind period; OL = Open-label period. Hy's law is defined as an elevated alanine aminotransferase level (\>3xULN) or an elevated aspartate aminotransferase (\>3xULN) in combination with alkaline phosphatase \<2xULN and elevated total bilirubin (\>2 x ULN). Study baseline is defined as last non-missing assessment prior to the first dose of study drug. Open-label baseline is defined as last non-missing assessment prior to the first dose of study drug in the open-label part.
| Participants | Double-Blind Part: KarXT | Double-Blind Part: Placebo | Open-Label Part: KarXT/KarXT | Open-Label Part: Placebo/KarXT |
|---|---|---|---|---|
| Study Baseline - Alanine aminotransferase - >3XULN | 0 | 0 | 0 | 0 |
| Study Baseline - Alanine aminotransferase - >5XULN | 0 | 0 | 0 | 0 |
| Study Baseline - Alanine aminotransferase - >8XULN | 0 | 0 | 0 | 0 |
| Study Baseline - Alanine aminotransferase - >10XULN | 0 | 0 | 0 | 0 |
| Study Baseline - Alanine aminotransferase - >20XULN | 0 | 0 | 0 | 0 |
| Study Baseline - Aspartate Aminotransferase - >3XULN | 0 | 0 | 0 | 0 |
| Study Baseline - Aspartate Aminotransferase - >5XULN | 0 | 0 | 0 | 0 |
| Study Baseline - Aspartate Aminotransferase - >8XULN | 0 | 0 | 0 | 0 |
| Study Baseline - Aspartate Aminotransferase - >10XULN | 0 | 0 | 0 | 0 |
| Study Baseline - Aspartate Aminotransferase - >20XULN | 0 | 0 | 0 | 0 |
| Study Baseline - Alkaline phosphatase - >1.5XULN | 0 | 0 | 0 | 0 |
| Study Baseline - Alkaline phosphatase - >2XULN | 0 | 0 | 0 | 0 |
| Study Baseline - Bilirubin - >1.5XULN | 0 | 2 | 0 | 1 |
| Study Baseline - Bilirubin - >2XULN | 0 | 0 | 0 | 0 |
| Study Baseline - Gamma glutamyl transferase - >2XULN | 1 | 1 | 1 | 0 |
| Study Baseline - Hy's law cases | 0 | 0 | 0 | 0 |
| Day 21 DB - Alanine aminotransferase - >3XULN | 5 | 0 | — | — |
| Day 21 DB - Alanine aminotransferase - >5XULN | 2 | 0 | — | — |
| Day 21 DB - Alanine aminotransferase - >8XULN | 1 | 0 | — | — |
| Day 21 DB - Alanine aminotransferase - >10XULN | 0 | 0 | — | — |
| Day 21 DB - Alanine aminotransferase - >20XULN | 0 | 0 | — | — |
| Day 21 DB - Aspartate Aminotransferase - >3XULN | 1 | 0 | — | — |
| Day 21 DB - Aspartate Aminotransferase - >5XULN | 1 | 0 | — | — |
| Day 21 DB- Aspartate Aminotransferase - >8XULN | 1 | 0 | — | — |
| Day 21 DB - Aspartate Aminotransferase - >10XULN | 1 | 0 | — | — |
| Day 21 DB - Aspartate Aminotransferase - >20XULN | 0 | 0 | — | — |
| Day 21 DB - Alkaline phosphatase - >1.5XULN | 2 | 0 | — | — |
| Day 21 DB - Alkaline phosphatase - >2XULN | 0 | 0 | — | — |
| Day 21 DB - Bilirubin - >1.5XULN | 0 | 2 | — | — |
| Day 21 DB - Bilirubin - >2XULN | 0 | 0 | — | — |
| Day 21 DB - Gamma glutamyl transferase - >2XULN | 9 | 1 | — | — |
| Day 21 DB - Hy's law cases | 0 | 0 | — | — |
| Day 35 DB - Alanine aminotransferase - >3XULN | 0 | 1 | — | — |
| Day 35 DB - Alanine aminotransferase - >5XULN | 0 | 0 | — | — |
| Day 35 DB - Alanine aminotransferase - >8XULN | 0 | 0 | — | — |
| Day 35 DB - Alanine aminotransferase - >10XULN | 0 | 0 | — | — |
| Day 35 DB - Alanine aminotransferase - >20XULN | 0 | 0 | — | — |
| Day 35 DB - Aspartate Aminotransferase - >3XULN | 0 | 0 | — | — |
| Day 35 DB - Aspartate Aminotransferase - >5XULN | 0 | 0 | — | — |
| Day 35 DB - Aspartate Aminotransferase - >8XULN | 0 | 0 | — | — |
| Day 35 DB - Aspartate Aminotransferase - >10XULN | 0 | 0 | — | — |
| Day 35 DB - Aspartate Aminotransferase - >20XULN | 0 | 0 | — | — |
| Day 35 DB - Alkaline phosphatase - >1.5XULN | 0 | 1 | — | — |
| Day 35 DB - Alkaline phosphatase - >2XULN | 0 | 1 | — | — |
| Day 35 DB - Bilirubin - >1.5XULN | 0 | 4 | — | — |
| Day 35 DB - Bilirubin - >2XULN | 0 | 0 | — | — |
| Day 35 DB - Gamma glutamyl transferase - >2XULN | 3 | 2 | — | — |
| Day 35 DB - Hy's law cases | 0 | 0 | — | — |
| End of study - Alanine aminotransferase - >3XULN | 0 | 0 | 0 | 0 |
| End of study - Alanine aminotransferase - >5XULN | 0 | 0 | 0 | 0 |
| End of study - Alanine aminotransferase - >8XULN | 0 | 0 | 0 | 0 |
| End of study - Alanine aminotransferase - >10XULN | 0 | 0 | 0 | 0 |
| End of study - Alanine aminotransferase - >20XULN | 0 | 0 | 0 | 0 |
| End of study - Aspartate Aminotransferase - >3XULN | 0 | 0 | 0 | 0 |
| End of study - Aspartate Aminotransferase - >5XULN | 0 | 0 | 0 | 0 |
| End of study - Aspartate Aminotransferase - >8XULN | 0 | 0 | 0 | 0 |
| End of study - Aspartate Aminotransferase - >10XULN | 0 | 0 | 0 | 0 |
| End of study - Aspartate Aminotransferase - >20XULN | 0 | 0 | 0 | 0 |
| End of study - Alkaline phosphatase - >1.5XULN | 0 | 1 | 0 | 0 |
| End of study - Alkaline phosphatase - >2XULN | 0 | 0 | 0 | 0 |
| End of study - Bilirubin - >1.5XULN | 0 | 0 | 0 | 0 |
| End of study - Bilirubin - >2XULN | 0 | 0 | 0 | 0 |
| End of study - Gamma glutamyl transferase - >2XULN | 1 | 1 | 0 | 0 |
| End of study - Hy's law cases | 0 | 0 | 0 | 0 |
| Open-label baseline - Alanine aminotransferase - >3XULN | — | — | 0 | 0 |
| Open-label baseline - Alanine aminotransferase - >5XULN | — | — | 0 | 0 |
| Open-label baseline - Alanine aminotransferase - >8XULN | — | — | 0 | 0 |
| Open-label baseline - Alanine aminotransferase - >10XULN | — | — | 0 | 0 |
| Open-label baseline - Alanine aminotransferase - >20XULN | — | — | 0 | 0 |
| Open-label baseline - Aspartate Aminotransferase - >3XULN | — | — | 0 | 0 |
| Open-label baseline - Aspartate Aminotransferase - >5XULN | — | — | 0 | 0 |
| Open-label baseline - Aspartate Aminotransferase - >8XULN | — | — | 0 | 0 |
| Open-label baseline - Aspartate Aminotransferase - >10XULN | — | — | 0 | 0 |
| Open-label baseline - Aspartate Aminotransferase - >20XULN | — | — | 0 | 0 |
| Open-label baseline - Alkaline phosphatase - >1.5XULN | — | — | 0 | 0 |
| Open-label baseline - Alkaline phosphatase - >2XULN | — | — | 0 | 0 |
| Open-label baseline - Bilirubin - >1.5XULN | — | — | 0 | 0 |
| Open-label baseline - Bilirubin - >2XULN | — | — | 0 | 0 |
| Open-label baseline - Gamma glutamyl transferase - >2XULN | — | — | 1 | 0 |
| Open-label baseline - Hy's law cases | — | — | 0 | 0 |
| Day 14 OL - Alanine aminotransferase - >3XULN | — | — | 1 | 0 |
| Day 14 OL - Alanine aminotransferase - >5XULN | — | — | 0 | 0 |
| Day 14 OL - Alanine aminotransferase - >8XULN | — | — | 0 | 0 |
| Day 14 OL - Alanine aminotransferase - >10XULN | — | — | 0 | 0 |
| Day 14 OL - Alanine aminotransferase - >20XULN | — | — | 0 | 0 |
| Day 14 OL - Aspartate Aminotransferase - >3XULN | — | — | 0 | 0 |
| Day 14 OL - Aspartate Aminotransferase - >5XULN | — | — | 0 | 0 |
| Day 14 OL - Aspartate Aminotransferase - >8XULN | — | — | 0 | 0 |
| Day 14 OL - Aspartate Aminotransferase - >10XULN | — | — | 0 | 0 |
| Day 14 OL - Aspartate Aminotransferase - >20XULN | — | — | 0 | 0 |
| Day 14 OL - Alkaline phosphatase - >1.5XULN | — | — | 0 | 0 |
| Day 14 OL - Alkaline phosphatase - >2XULN | — | — | 0 | 0 |
| Day 14 OL - Bilirubin - >1.5XULN | — | — | 0 | 0 |
| Day 14 OL - Bilirubin - >2XULN | — | — | 0 | 0 |
| Day 14 OL - Gamma glutamyl transferase - >2XULN | — | — | 1 | 0 |
| Day 14 OL - Hy's law cases | — | — | 0 | 0 |
| Day 84 - OL - Alanine aminotransferase - >3XULN | — | — | 0 | 0 |
| Day 84 - OL - Alanine aminotransferase - >5XULN | — | — | 0 | 0 |
| Day 84 - OL - Alanine aminotransferase - >8XULN | — | — | 0 | 0 |
| Day 84 - OL - Alanine aminotransferase - >10XULN | — | — | 0 | 0 |
| Day 84 - OL - Alanine aminotransferase - >20XULN | — | — | 0 | 0 |
| Day 84 - OL - Aspartate Aminotransferase - >3XULN | — | — | 0 | 0 |
| Day 84 - OL - Aspartate Aminotransferase - >5XULN | — | — | 0 | 0 |
| Day 84 - OL - Aspartate Aminotransferase - >8XULN | — | — | 0 | 0 |
| Day 84 - OL - Aspartate Aminotransferase - >10XULN | — | — | 0 | 0 |
| Day 84 - OL - Aspartate Aminotransferase - >20XULN | — | — | 0 | 0 |
| Day 84 - OL - Alkaline phosphatase - >1.5XULN | — | — | 0 | 0 |
| Day 84 - OL - Alkaline phosphatase - >2XULN | — | — | 0 | 0 |
| Day 84 - OL - Bilirubin - >1.5XULN | — | — | 0 | 0 |
| Day 84 - OL - Bilirubin - >2XULN | — | — | 0 | 0 |
| Day 84 - OL - Gamma glutamyl transferase - >2XULN | — | — | 0 | 0 |
| Day 84 - OL - Hy's law cases | — | — | 0 | 0 |
ULN = Upper limit of normal; DB = Double-blind period; OL = Open-label period. Study baseline is defined as last non-missing assessment prior to the first dose of study drug. Open-label baseline is defined as last non-missing assessment prior to the first dose of study drug in the open-label part.
| Participants | Double-Blind Part: KarXT | Double-Blind Part: Placebo | Open-Label Part: KarXT/KarXT | Open-Label Part: Placebo/KarXT |
|---|---|---|---|---|
| Study baseline - Glucose > ULN | 14 | 18 | 6 | 8 |
| Study baseline - Total Cholesterol > ULN | 19 | 11 | 6 | 5 |
| Study baseline - Triglycerides > ULN | 18 | 20 | 5 | 8 |
| Day 21 DB - Glucose > ULN | 10 | 8 | — | — |
| Day 21 DB - Total Cholesterol > ULN | 7 | 6 | — | — |
| Day 21 DB - Triglycerides > ULN | 19 | 22 | — | — |
| Day 35 DB - Glucose > ULN | 12 | 12 | — | — |
| Day 35 DB - Total Cholesterol > ULN | 7 | 8 | — | — |
| Day 35 DB - Triglycerides > ULN | 18 | 25 | — | — |
| End of study - Glucose > ULN | 6 | 7 | 1 | 3 |
| End of study - Total Cholesterol > ULN | 5 | 4 | 4 | 1 |
| End of study - Triglycerides > ULN | 8 | 14 | 2 | 4 |
| Open-label baseline - Glucose > ULN | — | — | 6 | 3 |
| Open-label baseline - Total Cholesterol > ULN | — | — | 1 | 2 |
| Open-label baseline - Triglycerides > ULN | — | — | 9 | 6 |
| Day 14 OL - Glucose > ULN | — | — | 5 | 5 |
| Day 14 OL - Total Cholesterol > ULN | — | — | 3 | 2 |
| Day 14 OL - Triglycerides > ULN | — | — | 8 | 3 |
| Day 84 OL - Glucose > ULN | — | — | 1 | 2 |
| Day 84 OL - Total Cholesterol > ULN | — | — | 2 | 1 |
| Day 84 OL - Triglycerides > ULN | — | — | 2 | 2 |
Anytime post-baseline includes all assessments from the first dose of study drug until end of study visit in double-blind/open-label part, including unscheduled assessments. Study baseline is defined as last non-missing assessment prior to the first dose of study drug. Open-label baseline is defined as last non-missing assessment prior to the first dose of study drug in the open-label part.
| Participants | Double-Blind Part: KarXT | Double-Blind Part: Placebo | Open-Label Part: KarXT/KarXT | Open-Label Part: Placebo/KarXT |
|---|---|---|---|---|
| Baseline - QTcF > 450 msec | 3 | 0 | 3 | 0 |
| Baseline - QTcF > 480 msec | 0 | 0 | 0 | 0 |
| Baseline - QTcF > 500 msec | 0 | 0 | 0 | 0 |
| Baseline - PR ≥ 250 msec | 0 | 0 | 0 | 0 |
| Baseline - QRS Interval ≥ 150 msec | 0 | 0 | 0 | 0 |
| Anytime post baseline - QTcF > 450 msec | 2 | 2 | 1 | 0 |
| Anytime post baseline - QTcF > 480 msec | 0 | 0 | 1 | 0 |
| Anytime post baseline - QTcF > 500 msec | 0 | 0 | 0 | 0 |
| Anytime post baseline - QTcF Increase > 30 msec from study baseline | 17 | 21 | 4 | 6 |
| Anytime post baseline - QTcF Increase > 60 msec from study baseline | 2 | 0 | 0 | 2 |
| Anytime post baseline - QTcF Increase > 30 msec from open-label baseline | — | — | 4 | 6 |
| Anytime post baseline - PR ≥ 250 msec | 0 | 0 | 0 | 0 |
| Anytime post baseline - QTcF Increase > 60 msec from open-label baseline | — | — | 1 | 0 |
| Anytime post baseline - QRS Interval ≥ 150 msec | 1 | 0 | 0 | 0 |
The C-SSRS is a clinician- or self-administered questionnaire assessing suicidal ideation and behavior. It rates ideation severity from 1 (wish to be dead) to 5 (active suicidal ideation with specific plan and intent). It also records the presence or absence of suicidal behaviors, including actual, interrupted, or aborted attempts, and preparatory acts. The highest level of ideation or most severe behavior reported is used to determine suicide risk; higher ideation scores or any suicidal behavior indicate greater risk. Baseline is the last non-missing assessment before first study drug dose.
| Participants | Double-Blind Part: KarXT | Double-Blind Part: Placebo | Open-Label Part: KarXT/KarXT | Open-Label Part: Placebo/KarXT |
|---|---|---|---|---|
| Post-Baseline Suicidal ideation (SI) - Any Suicidal Ideation | 7 | 4 | 1 | 3 |
| Post-Baseline Suicidal ideation - Wish to be Dead | 5 | 4 | 1 | 3 |
| Post-Baseline Suicidal ideation - Non-Specific Active Suicidal Thoughts | 6 | 3 | 1 | 1 |
| Post-Baseline SI - Active Suicidal Ideation with any Methods without Intent to Act | 1 | 2 | 0 | 1 |
| Post-Baseline SI - Active Suicidal Ideation with Some Intent to Act without Specific Plan | 1 | 1 | 0 | 1 |
| Post-Baseline Suicidal ideation - Active Suicidal Ideation with Specific Plan and Intent | 1 | 0 | 0 | 1 |
Treatment-emergent parkinsonism is defined as Simpson-Angus Scale total score \>3 with a baseline score ≤3. Treatment-emergent akathisia is defined as Barnes Akathisia Rating Scale global clinical assessment score \>2 with a baseline score ≤2. Treatment-emergent dyskinesia is defined as any Abnormal Involuntary Movement Scale (AIMS) item 1-7 score ≥3 with a baseline score \<3 for the item, or score ≥2 on two or more of AIMS items 1-7 with baseline \<2 for the items. Study baseline is defined as last non-missing assessment prior to the first dose of study drug. Open-label baseline is defined as last non-missing assessment prior to the first dose of study drug in the open-label part.
| Participants | Double-Blind Part: KarXT | Double-Blind Part: Placebo | Open-Label Part: KarXT/KarXT | Open-Label Part: Placebo/KarXT |
|---|---|---|---|---|
| Treatment-Emergent Parkinsonism with respect to study baseline | 3 | 2 | 1 | 1 |
| Treatment-Emergent Akathisia with respect to study baseline | 2 | 3 | 0 | 0 |
| Treatment-Emergent Dyskinesia with respect to study baseline | 0 | 2 | 0 | 1 |
| Treatment-Emergent Parkinsonism with respect to open-label baseline | — | — | 2 | 0 |
| Treatment-Emergent Akathisia with respect to open-label baseline | — | — | 0 | 0 |
| Treatment-Emergent Dyskinesia with respects to open-label baseline | — | — | 0 | 1 |
Study baseline is defined as last non-missing assessment prior to the first dose of study drug. Open-label baseline is defined as last non-missing assessment prior to the first dose of study drug in the open-label part.
| Kg | Double-Blind Part: KarXT | Double-Blind Part: Placebo | Open-Label Part: KarXT/KarXT | Open-Label Part: Placebo/KarXT |
|---|---|---|---|---|
| Day 35 change from study baseline | -2.125 ± 2.9596 | -1.184 ± 3.1079 | — | — |
| Day 84 change from study baseline | — | — | -2.889 ± 6.7846 | -6.955 ± 5.0021 |
| Day 84 change from open-label baseline | — | — | -1.222 ± 5.2847 | -4.182 ± 2.9634 |
| End of study change from study baseline | -2.773 ± 3.1119 | -0.646 ± 3.3921 | -2.533 ± 6.4198 | -4.995 ± 5.2225 |
| End of study change from open-label baseline | — | — | -1.462 ± 5.1589 | -2.850 ± 3.2432 |
Study baseline is defined as last non-missing assessment prior to the first dose of study drug. Open-label baseline is defined as last non-missing assessment prior to the first dose of study drug in the open-label part.
| Kg/m2 | Double-Blind Part: KarXT | Double-Blind Part: Placebo | Open-Label Part: KarXT/KarXT | Open-Label Part: Placebo/KarXT |
|---|---|---|---|---|
| Day 35/Week 5 Change from Study baseline | -0.79 ± 1.106 | -0.43 ± 1.135 | — | — |
| Day 84/Week 12 Change from Study baseline | — | — | -1.10 ± 2.692 | -2.61 ± 1.983 |
| Day 84/Week 12 Change from open-label baseline | — | — | -0.46 ± 2.121 | 1.59 ± 1.276 |
| End of Study Change from Study baseline | -1.01 ± 1.133 | -0.22 ± 1.193 | -0.92 ± 2.499 | -1.83 ± 1.930 |
| End of Study Change from open-label baseline | — | — | -0.52 ± 2.046 | -1.05 ± 1.224 |
Study baseline is defined as last non-missing assessment prior to the first dose of study drug. Open-label baseline is defined as last non-missing assessment prior to the first dose of study drug in the open-label part.
| cm | Double-Blind Part: KarXT | Double-Blind Part: Placebo | Open-Label Part: KarXT/KarXT | Open-Label Part: Placebo/KarXT |
|---|---|---|---|---|
| Day 35/Week 5 Change from Study baseline | -2.27 ± 4.070 | -1.01 ± 3.269 | — | — |
| Day 84/Week 12 Change from Study baseline | — | — | -3.96 ± 8.288 | -4.82 ± 6.416 |
| Day 84/Week 12 Change from open-label baseline | — | — | -1.88 ± 7.198 | -2.27 ± 4.671 |
| End of Study Change from Study baseline | -3.40 ± 4.155 | -1.34 ± 4.167 | -4.69 ± 8.183 | -3.39 ± 5.345 |
| End of Study Change from open-label baseline | — | — | -3.12 ± 6.874 | -2.45 ± 2.543 |
AUC₀-12 (Area Under the Concentration-Time Curve from time zero to 12 hours) is the total amount of drug in the blood measured from the time the drug is given (time zero) up to 12 hours after dosing.
| pg*h/mL | Double-Blind Part: KarXT | Double-Blind Part: Placebo |
|---|---|---|
| Day 28 - Xanomeline 100/20 | 93200 ± 89.9 | — |
| Day 28 - Xanomeline 125/30 | 87100 ± 75.9 | — |
| Day 28 - Trospium 100/20 | 48600 ± 70.4 | — |
| Day 28 - Trospium 125/30 | 47900 ± 81.9 | — |
Cmax is the highest concentration of a drug measured in the blood after it is given.
| pg/mL | Double-Blind Part: KarXT | Double-Blind Part: Placebo |
|---|---|---|
| Day 28 - Xanomeline 100/20 | 16000 ± 129.1 | — |
| Day 28 - Xanomeline 125/30 | 15900 ± 95.9 | — |
| Day 28 - Trospium 100/20 | 11100 ± 139.7 | — |
| Day 28 - Trospium 125/30 | 9330 ± 99.3 | — |
Tmax is the amount of time it takes to reach that highest concentration (Cmax) after the drug is given.
| Hours | Double-Blind Part: KarXT | Double-Blind Part: Placebo |
|---|---|---|
| Day 28 - Xanomeline 100/20 | 1.70 (0.00 to 11.97) | — |
| Day 28 - Xanomeline 125/30 | 1.93 (0.00 to 11.95) | — |
| Day 28 - Trospium 100/20 | 0.56 (0.00 to 11.90) | — |
| Day 28 - Trospium 125/30 | 0.97 (0.42 to 2.07) | — |
Collected over Double-blind part: From the start of study drug administration up to week 5. Open-label extension part: From the start of study drug administration up to week 12. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Double-Blind Part: KarXT | 0/103 (0%) | 0/102 (0%) | 97/102 (95.1%) |
| Double-Blind Part: Placebo | 0/99 (0%) | 3/98 (3.1%) | 90/98 (91.8%) |
| Open-Label Part: KarXT/KarXT | 0/38 (0%) | 0/38 (0%) | 33/38 (86.8%) |
| Open-Label Part: Placebo/KarXT | 1/28 (3.6%) | 3/28 (10.7%) | 28/28 (100%) |
| Event | Double-Blind Part: KarXT | Double-Blind Part: Placebo | Open-Label Part: KarXT/KarXT | Open-Label Part: Placebo/KarXT |
|---|---|---|---|---|
| SchizophreniaPsychiatric disorders | 0/102 | 2/98 | 0/38 | 2/28 |
| Completed suicidePsychiatric disorders | 0/102 | 0/98 | 0/38 | 1/28 |
| Suicidal ideationPsychiatric disorders | 0/102 | 0/98 | 0/38 | 1/28 |
| Spinal compression fractureInjury, poisoning and procedural complications | 0/102 | 1/98 | 0/38 | 0/28 |
| Event | Double-Blind Part: KarXT | Double-Blind Part: Placebo | Open-Label Part: KarXT/KarXT | Open-Label Part: Placebo/KarXT |
|---|---|---|---|---|
| VomitingGastrointestinal disorders | 48/102 | 2/98 | 10/38 | 20/28 |
| NauseaGastrointestinal disorders | 38/102 | 5/98 | 5/38 | 14/28 |
| Weight decreasedInvestigations | 21/102 | 16/98 | 11/38 | 10/28 |
| ConstipationGastrointestinal disorders | 32/102 | 20/98 | 6/38 | 8/28 |
| Decreased appetiteMetabolism and nutrition disorders | 8/102 | 4/98 | 1/38 | 7/28 |
| TachycardiaCardiac disorders | 20/102 | 2/98 | 2/38 | 3/28 |
| DizzinessNervous system disorders | 20/102 | 5/98 | 1/38 | 3/28 |
| Sinus tachycardiaCardiac disorders | 17/102 | 2/98 | 0/38 | 3/28 |
| Orthostatic hypotensionVascular disorders | 16/102 | 14/98 | 4/38 | 3/28 |
| DiarrhoeaGastrointestinal disorders | 12/102 | 3/98 | 2/38 | 4/28 |
Open-Label participants are accounted for under their Double-Blind Groups
| Age, Continuous(Years) | Double-Blind Part: KarXT | Double-Blind Part: Placebo | Open-Label Part: KarXT/KarXT | Open-Label Part: Placebo/KarXT | Total |
|---|---|---|---|---|---|
| Mean | 37.3 ± 9.55 | 36.9 ± 11.91 | — | — | 37.1 ± 10.75 |
| Sex: Female, Male(Participants) | Double-Blind Part: KarXT | Double-Blind Part: Placebo | Open-Label Part: KarXT/KarXT | Open-Label Part: Placebo/KarXT | Total |
|---|---|---|---|---|---|
| Female | 56 | 50 | — | — | 106 |
| Male | 47 | 49 | — | — | 96 |
| Ethnicity (NIH/OMB)(Participants) | Double-Blind Part: KarXT | Double-Blind Part: Placebo | Open-Label Part: KarXT/KarXT | Open-Label Part: Placebo/KarXT | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | — | — | 0 |
| Not Hispanic or Latino | 103 | 99 | — | — | 202 |
| Unknown or Not Reported | 0 | 0 | — | — | 0 |
| Race (NIH/OMB)(Participants) | Double-Blind Part: KarXT | Double-Blind Part: Placebo | Open-Label Part: KarXT/KarXT | Open-Label Part: Placebo/KarXT | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | — | — | 0 |
| Asian | 103 | 99 | — | — | 202 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | — | — | 0 |
| Black or African American | 0 | 0 | — | — | 0 |
| White | 0 | 0 | — | — | 0 |
| More than one race | 0 | 0 | — | — | 0 |
| Unknown or Not Reported | 0 | 0 | — | — | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2023 to primary completion in Sep 2024, 15 months.
Results were first posted in Nov 2025, 1 year 2 months after primary completion.
Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's 15 months is below that.
Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Xanomeline · Trospium chloride
Karuna Therapeutics, Inc., a Bristol Myers Squibb company →